BioSpace News Archive

Mydecine Innovations Group, an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced the filing of seven provisional patent applications with the United States Patent and Trademark Office in its efforts to discover valuable novel compounds in fungi for medicinal and pharmaceutical use.

Resubmitted revised dosing regimen for Libervant to FDA in December 2020, as committed Multiple clinical trials demonstrate that AQST-108 can consistently deliver epinephrine

BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), announced today that the U.S. Food and Drug Administration (FDA) has cleared their Investigational New Drug (IND) application to proceed with a Phase 1 (Ph1) study in patients with advanced Parkinson’s disease (PD).

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the “Company” or “Biohaven”) today announced the acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. (“Kleo”) that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab

The Supervisory Board of Synthon BV, an international, science-centered pharmaceutical company specialized in developing and manufacturing high-quality generic and hybrid medicines for patients around the world, is pleased to announce that Anish Mehta is appointed as Chief Executive Officer and member of the Board of Directors, effective immediately.

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the year ended December 31, 2020. Beginning with the first quarter of 2020, the Company has been providing a preliminary look at the top

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, January 14, 2021 at 4:30 p.m. Eastern Time. A live audio webcast of the corporate presentation and question and answer ses

Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX: VMD.TO and NASDAQ:VMD), a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced a recently completed non-invasive ventilation study led by Dr. William Frazier, Viemed’s Chief Medical Officer.

AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will be participating in this year’s Biotech Showcase Digital 2021 conference. James Sapirstein, President & CEO of AzurRx BioPharma, and the Company’s senior management team will be participating in virtual one-on-one meet

MYND Life Sciences Inc. a life sciences company focused on novel psychedelic drug development and pharmaceuticals, is pleased to announce the closing of a non-brokered private placement offering by the Company of an aggregate of 8,000,000 common shares at a price of CDN$0.30 per Common Share for aggregate gross proceeds of CDN$2.4 million.